Evolute Institute · Safety Hub · Dosage
Your Psilocybin Truffle Dosage, Measured in Milligrams
Psilocybin truffle dosage is normally estimated from how much the truffles weigh. Starting Q3 2026, Evolute measures the actual psilocybin content of the specific batch used at each retreat and sets every participant's dose in milligrams of psilocybin instead.
To our knowledge, Evolute is the first non-clinical psilocybin retreat provider in Europe to make measured concentration a standard part of how every participant's dose is set. The assay was developed at Friedrich Schiller University Jena with German federal and European Social Fund backing, and is validated to within about 10% of laboratory-grade HPLC.
Psilocybin concentration testing is the practice of measuring the actual psilocybin content of the specific truffle batch used at a retreat, rather than inferring it from the batch's weight. Instead of being told “you will take X grams of truffles,” participants have their psilocybin dosage calculated and communicated in milligrams. This page explains why that distinction matters, how the measurement works, and what changes for participants.
How much psilocybin is actually in a truffle dose?
That depends on the strain and the batch, and the weight of the truffles will not tell you. A 2024 laboratory study using liquid chromatography-tandem mass spectrometry measured five commercially sourced Psilocibo cubensis strains and found average combined psilocybin and psilocin content ranging from 0.88% to 1.36% of dry weight (Goff et al., 2024). A 2022 clinical review names this same variability as one of the practical obstacles to dosing natural products consistently (MacCallum, Lo, Pistawka, & Deol, 2022).
A 2026 peer-reviewed field study shows what that variability means in a live retreat. Pérez Rosal and Faber deployed the same class of colorimetric assay Evolute is adopting at a seven-day retreat in Jamaica with eleven participants, measuring the actual material used in two sessions held 48 hours apart (Pérez Rosal & Faber, 2026). The first session used a 1:1 blend of two strains measuring 6.08 mg of psilocybin per gram. The second used a single, different strain measuring 15.7 mg/g, a 2.6-fold difference in potency between the two materials.
Because that team measured concentration instead of assuming it, they could weigh each participant's dose to a known milligram target: 15.2-21.3 mg in the first session, and a deliberately higher 47.1-70.7 mg in the second, raised on purpose to offset the acute tolerance that builds after a recent psilocybin session. The deliberate control is the point. Had those same two materials been dosed by weight alone, still the standard across the retreat field, a 2.6-fold potency gap would have passed straight through to participants, unseen and unintended.
Weight has been the only practical proxy available outside a laboratory. It is a reasonable stand-in when nothing better exists. It is still a stand-in, resting on an assumed average potency that a specific batch may not have.
| Dosing by weight | Dosing by measured concentration | |
|---|---|---|
| Dose expressed as | Grams of truffles | Milligrams of psilocybin |
| Basis | Assumed average potency | Measured concentration of the actual batch |
| Batch variability | Not visible | Measured, then adjusted for |
| Comparable to | An informed estimate | The dosing logic used in clinical trials |
How is psilocybin truffle dosage measured?
With a quantitative colorimetric assay, a simplified, field-deployable adaptation of the analysis normally performed by HPLC. A small, homogenised sample of dried truffle material is crushed and mixed with an extraction liquid. The extract is added to a detection solution that develops a colour complex whose intensity is proportional to the amount of active compound present. A photometer then reads that intensity and reports a numerical value. The sample is homogenised precisely because psilocybin is not distributed evenly through fungal material, so a single piece is not representative of the batch.
Rather than confirming only that psilocybin is present, the test quantifies total alkaloid content, psilocybin plus psilocin (its active metabolite), as a single total psilocybin concentration, across a working range of roughly 0.1-2.5%, with results validated to within about 10% of HPLC.
The assay was developed at the Friedrich Schiller University Jena Institute of Pharmacy, under a project funded by the German federal government and the European Social Fund and led by Dr. Felix Blei. It has been validated against reference standards at university level and calibrated through instrumental analysis.
How will my dose be calculated at the retreat?
In milligrams of psilocybin, based on the measured concentration of the specific batch being used at your retreat, rather than as an approximate number of grams of truffle. The facilitation team can then adjust the amount of truffle material up or down to reach an intended, individualised dose, instead of assuming a fixed batch potency.
Nothing else about the programme changes. The same medical and psychiatric screening, reviewed by a licensed psychiatrist rather than a facilitator. The same Rácio facilitador-participante de 1:2. The same Medical Doctor physically present on-site throughout the ceremony, not on call. What changes is what the word dose refers to: a quantity someone has actually measured.
How does this compare to clinical trial dosing?
Clinical psilocybin trials dose participants in milligrams of synthesised psilocybin, a precisely known quantity, identical from session to session. Retreats using natural truffles have generally not matched that precision, because the variability in the product was assumed rather than measured. Direct concentration testing does not make truffles synthetic or standardised the way a clinical capsule is. It replaces an assumption with a measurement, on the actual batch being used at your retreat.
EvoSHIFT remains a non-clinical, evidence-informed personal development programme. Concentration testing is a safety and transparency measure applied to the product itself, not a change to the programme's framing or claims. It also reflects a direction the harm-reduction field is already moving in: a 2025 academic review of drug-checking for classic psychedelics treats field-deployable potency quantification as part of the harm-reduction toolkit for this drug class (Hirschfeld, Blei, Stegemann, van der Gouwe, & Smit-Rigter, 2025).
You can see how this sits alongside Evolute's other published safety commitments in the Quadro de Avaliação da Psilocibina Retreat, how EvoSHIFT reports against that framework in the Declaração voluntária do prestador de serviços EvoSHIFT, and the medical and psychiatric side of screening on Contraindicações da psilocibina Retreat.
Curioso? Vamos conversar.
Marque uma chamada gratuita connosco e vamos discutir quaisquer dúvidas ou preocupações que possa ter. Vamos ajudá-lo a determinar se este programa se adequa às suas necessidades atuais e garantir que se sinta preparado e confiante para embarcar nesta jornada transformadora.
"Estamos aqui para estar ao serviço da vossa viagem." - Dr. Dmitrij Achelrod · Cofundador
Se preferir passar diretamente para uma candidatura, pode começa aqui.
Referências
- Goff, R. et al. (2024). Determination of psilocybin and psilocin content in multiple Psilocybe cubensis mushroom strains using liquid chromatography-tandem mass spectrometry. Analytica Chimica Acta, 1288, 342161. https://doi.org/10.1016/j.aca.2023.342161
- Hirschfeld, T., Blei, F., Stegemann, L., van der Gouwe, D., & Smit-Rigter, L. (2025). Psychedelic drug checking: Analytical and strategic challenges in harm reduction for classic psychedelics. Current Topics in Behavioral Neurosciences. Springer. https://doi.org/10.1007/7854_2025_606
- MacCallum, C.A., Lo, L.A., Pistawka, C.A., & Deol, J.K. (2022). Therapeutic use of psilocybin: Practical considerations for dosing and administration. Frontiers in Psychiatry, 13, 1040217. https://doi.org/10.3389/fpsyt.2022.1040217
- Pérez Rosal, S.R., & Faber, S.C. (2026). Quantifying psilocybin exposure in a natural product-based retreat setting: An observational field method for dose measurement. Psychedelics, 4, 100029. https://doi.org/10.1016/j.psyche.2026.100029
The Pérez Rosal & Faber (2026) study is a field-method feasibility demonstration with eleven participants at a single retreat, using dried Psilocibo cubensis mushroom material rather than Dutch truffles. Its authors are explicit that it is not a population-level safety or dosing-efficacy study. The potency and dose figures cited above are its own directly measured results.
FAQ: Psilocybin Truffle Dosage
What dose of psilocybin will I actually receive?
A dose set individually for you and expressed in milligrams of psilocybin rather than grams of truffle. It is agreed during preparation with your facilitator, informed by your history, your intentions, and what the medical and psychiatric screening surfaced. From Q3 2026 that figure is calculated from the measured concentration of the specific batch at your retreat, so the amount of truffle material is adjusted to reach it rather than assumed.
Is Evolute really the first retreat provider to dose by measured concentration?
To the best of our knowledge, Evolute is the first non-clinical psilocybin retreat provider in Europe to make measured concentration a standard part of how every participant’s dose is set. Concentration testing has been done inside a retreat before – the 2026 field study cited on this page did exactly that in Jamaica, as a research protocol at a single retreat. What we are not aware of is a European non-clinical provider using measured concentration as routine practice at every retreat. This is a good-faith claim based on current knowledge of the field, not an audited market survey, and we will revise it if a comparable provider becomes known to us.
Does this change how strong my experience will be?
It changes the precision of what you are told about your dose, not our
approach to dosing. The aim is an accurate picture of what you are taking, not a stronger or weaker experience.
Does measuring the dose make this a clinical treatment?
No, and this is worth being precise about. Measuring concentration moves retreat dosing closer to the precision of a clinical standard. It does not make a retreat a clinical setting, and a retreat will never be one. EvoSHIFT remains a non-clinical, evidence-informed personal development programme. What the measurement changes is the accuracy of a single number. It does not change what the programme is, what it claims, or what it can responsibly offer you.